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Abstract 
Background: Emerging evidence points to potential roles of the humoral immune responses in the 
development of pancreatic cancer. Epidemiological studies have suggested involvement of viral and 
bacterial infections in pancreatic carcinogenesis. Experimental studies have reported high expression 
levels of antigens in pancreatic cancer cells. Therefore, we aimed to investigate the role of different 
components of humoral immunity in the context of pancreatic cancer. We evaluated associations 
between pre-diagnostic serum markers of the overall humoral immune system (immunoglobulin A 
(IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM)), and the risk of pancreatic cancer in the 
Swedish Apolipoprotein-related MORtality RISk (AMORIS) study. 
Methods: We selected all participants (≥20 years old) with baseline measurements of IgA, IgG or IgM 
(n= 41900, 136221, and 29919, respectively). Participants were excluded if they had a history of 
chronic pancreatitis and individuals were free from pancreatic cancer at baseline. Multivariate Cox 
proportional hazards regression was used to estimate risk of pancreatic cancer for medical cut-offs of 
IgA, IgG and IgM. 
Results: Compared to the reference level of 6.10-14.99 g/L, risk of pancreatic cancer was elevated 
among those with IgG levels <6.10 g/L [HR: 1.69 (95% CI 0.99-2.87)], and an inverse association was 
observed among those with IgG levels ≥15.00 g/L [0.82 (95% CI 0.64-1.05); Ptrend = 0.027]. The 
association appeared to be stronger for women than men [HR: 0.64 (95% CI 0.43-0.97) and 0.95 (95% 
CI 0.69-1.29) respectively]. No associations were observed with IgA or IgM.  
Conclusion: An inverse association was observed between pre-diagnostic serum levels of IgG and risk 
of pancreatic cancer. Our findings highlight the need to further investigate the role of immune 
response in pancreatic cancer aetiology.  
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Introduction 
Pancreatic cancer is predicted to be the second leading cause of cancer-related death by 2030 (1), and 
is frequently diagnosed at an advanced stage. To date, the aetiology of pancreatic cancer is not well 
understood (2). Apart from smoking (3), long-standing diabetes (4), obesity and chronic pancreatitis 
(5), little is known about the risk factors and biological processes that lead to pancreatic cancer 
development (6, 7).  
 
Recently, there has been mounting evidence that the humoral immune system plays a role in the 
development of pancreatic cancer. Epidemiological studies have suggested that viral and bacterial 
infections contribute to pancreatic cancer pathogenesis (8-13). Most studies focused on humoral 
responses to Helicobacter pylori and found contradicting results (14-17). More recently, periodontal 
disease, caused by bacterial infections of pathogens such as Porphyromonas gingivalis and 
Fusobacterium species, has been suggested to play a role in the development and prognosis of 
pancreatic cancer (18-24). Furthermore, other responses of the humoral immune system, such as 
allergic reactions, may present a protective effect for pancreatic cancer diagnosis (25-29).  
 
In addition to the epidemiological studies, experimental studies have reported a number of antigens 
that are highly expressed in pancreatic cancer cells (30, 31). For example, significant levels of 
immunoglobulin (Ig) G antibodies have been detected in cancer patients’ plasma, including in 
pancreatic cancer patients. More specifically, anti‐MUC1 serum IgG levels and IgG serum IgG4 
concentrations (>135 mg/dL) have been measured in patients with pancreatic cancer (32-34) . In 
contrast, no data is available for other antibodies such as IgA and IgM in relation with pancreatic 
cancer.  
 
Despite the growing evidence for a role of the humoral immune system in pancreatic cancer 
development, to our knowledge no epidemiological studies have yet evaluated the association 
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between pre-diagnostic serum markers of the overall humoral immune response and risk of pancreatic 
cancer. A better understanding of the aetiology and underlying biological mechanisms for pancreatic 
cancer may improve our ability to identify high risk individuals and improve early detection.  
 
We therefore present the first large population-based prospective cohort study to examine pre-
diagnostic markers of the overall humoral immune response (IgG, IgA, and IgM) in relation to 
pancreatic cancer.   
 
Materials and Methods 
Study population and data collection 
The Swedish Apolipoprotein-related MORtality RISk (AMORIS) cohort includes information from blood 
and urine samples for 812,073 subjects obtained and analysed between 1985 and 1996. All laboratory 
analyses were conducted at the Central Automation Laboratory (CALAB), Stockholm. The subjects 
were residents of Sweden and were predominantly living in the Stockholm county, ranging in age from 
less than 20 to over 80 years old. All participants were either healthy individuals referred for clinical 
laboratory testing as part of health check-ups or outpatients referred for laboratory testing (35). A 
more detailed description of the AMORIS cohort is given elsewhere (36-40).  
 
The AMORIS cohort has been followed via record linkage using the Swedish 10-digit personal identity 
number in Swedish national health registers, registers of quality of care, and surveys including socio-
economic data as well as a questionnaire and biomedical data from number of research cohorts (40). 
For the purpose of the current study, the National Cancer Register, the Patient Register, the Cause of 
death Register and the consecutive Swedish Censuses during 1970-1990 have been utilized. This study 
complied with the Declaration of Helsinki and was approved by the Ethics Review Board of the 
Karolinska Institutet. 
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This study included all individuals aged 20 years or older who were free from pancreatic cancer at 
baseline, as registered in the National Cancer Register dating back to 1958. Furthermore, participants 
were excluded if they had a history of chronic pancreatitis, as defined in the National Patient Register 
going back nationally to 1987 and regionally to 1964. All subjects were required to have a baseline 
measurement of IgA or IgG or IgM measured at a health examination between 1985 and 1996. If a 
participant had multiple measurements of an immunoglobulin, the first measurement was included in 
the study to allow for consistency across the entire cohort. Follow-up time was defined as time from 
baseline measurement until date of cancer diagnosis, death, emigration, or end of the study (31st of 
December 2011), whichever occurred first.  
 
The main outcome variable was a diagnosis of pancreatic cancer (International Classification of 
Diseases (ICD), Revision 7 (1955) code 157). We also included the following information from the 
AMORIS study: serum IgA (g/L), serum IgG (g/L), serum IgM (g/L), serum glucose (mmol/L), age at 
baseline measurement and gender. From the other registries, we collected information regarding 
education, Charlson Comorbidity Index (CCI) and socioeconomic status (SES). 
 
The quantitative determination of IgA, IgG and IgM was performed using turbidimetry with reagents 
(DAKO – Glostrup, Denmark) using a HITACHI 911 automatic analyser (Boehringer – Mannheim, 
Germany) with a coefficient of variation <5 % (IgA), ≤5 % (IgG) and ≤7 % (IgM) (41-43).   
 
Data analyses 
We estimated the risk of pancreatic cancer with multivariate Cox proportional hazards regression for 
medical cut-offs used in the CALAB laboratory of IgG (<6.10, 6.10-14.99, ≥15.00 g/L) (42). IgA was 
dichotomised as <3.66 g/L and ≥3.66 g/L instead of the medical cut-offs (<0.70, 0.70-3.65, ≥3.66 g/L) 
due to the small number of participants with low IgA levels (41, 44). Levels of IgM were dichotomised 
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as <1.40 g/L and ≥1.40 g/L, as proposed by the normal laboratory values for blood, plasma and serum 
from the MSD manual (45).  
 
Multivariate Cox proportional hazards regression models were adjusted for age, gender, education, 
CCI and serum glucose level (continuous variable). A test for trend was conducted by using assignment 
to medical cut-offs as an ordinal scale for IgG. To assess reverse causation, a sensitivity analysis was 
conducted in which those who had a follow-up time <1 year and <3 years, respectively, were removed.  
 
With regards to IgG, we performed stratified analyses for age (<55 & ≥55), gender (male & female) 
and serum glucose levels (<7.00 mmol/L & ≥7.00 mmol/L). A P-value for interaction was calculated.  
 
Finally, restrictive Cubic Spline (RCS) function was used to graphically display the hazard ratios 
representing the dose-response association between IgG and the risk of pancreatic cancer. We used 
knots located at the 5th, 50th and 95th percentiles. This analysis was performed using the RCS_RegSAS 
Macro created by Desquibet and Mariotti (46). All statistical analyses were conducted with Statistical 
Analysis Systems (SAS) release 9.4 (SAS Institute, Cary, NC). 
 
Results 
Immunoglobulin G 
Characteristics of study participants with a measurement of IgG are shown in Table 1. During a mean 
follow-up of 21.3 years, 689 participants developed pancreatic cancer. The mean age at measurement 
in participants who later developed pancreatic cancer was higher (55.8 yrs) than in participants 
without pancreatic cancer (47.1 yrs).  
 
Multivariate Cox regression (adjusted for age, gender, education, CCI and serum glucose level) for the 
association between immunoglobulin G and the risk of pancreatic cancer showed that, compared to 
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the IgG reference level of 6.10-14.99 g/L, there was a positive association for those with IgG levels 
<6.10 g/L [HR: 1.69 (95% CI 0.99-2.87)]. We also found an inverse association for those with IgG levels 
≥15.00 g/L [0.82 (95% CI 0.64-1.05); Ptrend = 0.027] (Table 2). A sensitivity analysis to assess reverse 
causation by excluding those with follow-up time <1 year and <3 year did not affect the above findings 
(results not shown). 
 
Stratified analysis by gender showed a similar inverse association between categories of IgG and the 
risk of developing pancreatic cancer. However, the strength of the association was more pronounced 
for women (P = 0.003) (Table 3). No effect modification by age and glucose levels was observed (results 
not shown). We further illustrated the association between serum IgG and the risk of developing 
pancreatic cancer through a dose-response curve with restrictive cubic splines (Figure 1). The direction 
of the hazard ratios observed in Tables 2 and 3 was consistent with shape of the curve, which 
presented a positive association for IgG levels lower than 11.00 g/L with pancreatic cancer risk and a 
protective effect for high levels of IgG (11.00 -20.00 g/L).  
 
Immunoglobulin A & immunoglobulin M 
Characteristics of study participants with a measurement of IgA are shown in Table 4. During a mean 
follow-up of 16.5 years, 169 participants developed pancreatic cancer. Characteristics of study 
participants with a measurement of IgM are shown in Table 6. During a mean follow-up of 15.4 years, 
117 participants developed pancreatic cancer.  
We found no association between immunoglobulin A or immunoglobulin M and the risk of pancreatic 
cancer (Tables 5 & 7). 
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Discussion 
In this project, we indicate the presence of an inverse association between serum IgG levels and the 
risk of developing pancreatic cancer in the Swedish AMORIS cohort. The inverse association was 
stronger in females compared with males. Pre-diagnostic serum levels of IgA or IgM did not show any 
association with the risk of pancreatic cancer.  
 
The immune system has been thought to modulate the development and evolution of pancreatic 
cancer (47). Tobacco smoking, chronic pancreatitis, obesity and long-standing diabetes are established 
risk factors for pancreatic cancer (4, 5, 48, 49). All these risk factors can influence the immune 
response, induce the formation of pre-malignant lesions and stimulate pancreatic cancer 
development (50, 51). Pancreatic cancer tissue contains multiple immunosuppressive cell types, 
suggesting an impairment of the immune response in the tumour micro-environment (51). Evidence 
is growing for the role of  the tumour-infiltrating B cells in the initiation and progression of pancreatic 
cancer (52). Tanaka et al., among other groups, also identified high serum levels of IgG on advanced 
pancreatic patients indicating IgG as a potential diagnostic test for pancreatic cancer (53).  
 
Recent experimental and epidemiological data suggest the importance of the microbiome in 
pancreatic cancer development and its potential use as a marker of disease susceptibility (9, 50, 54, 
55). Kau et al. highlighted the close interplay between life-style factors, such as diet and nutritional 
status, with the microbial ecology in the humans digestive system and its modulation of  the immune 
system (56). Moreover, there is increasing evidence of the influence of the microbiota in the 
development of human diseases such as obesity and diabetes, established risks factors for pancreatic 
cancer (57, 58). More specifically, exposure to the bacterium Helicobacter Pylori is suggested as a risk 
factor for pancreatic cancer (14-17). Data also suggest a positive association between periodontal 
disease, due to an infection of the periodontal bacterium Porphyromonas gingivalis and 
Fusobacterium species, and pancreatic cancer risk (8, 18-23). The microbiota immune modulation 
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promoting cancer pathogenesis has been explained  through inflammatory processes in the tumour 
tissue, however it has also been shown in mice that bacteria not present in the tumorigenic tissue can 
promote carcinogenesis, nor do they need to cause inflammation in the tumour microenvironment 
(8, 59).  New studies should further explore the interplay between lifestyle factors, microbiota and 
dysregulation of the immune system, which could provide new avenues to better understand the 
aetiology of pancreatic cancer. 
  
To our knowledge, this study is the first cohort that prospectively evaluate the association between 
pre-diagnostic serum markers of the overall humoral immune response and risk of pancreatic cancer. 
The observed inverse association between serum IgG and the risk of developing pancreatic cancer is 
consistent with the work by Michaud et al. (20): in a cluster analysis on oral bacteria antibodies, the 
cluster with overall higher levels of antibodies against 25 oral bacteria had a 45% lower risk of 
pancreatic cancer development than a cluster with overall lower levels of antibodies. This finding 
suggest that higher levels of antibodies against oral bacteria may reflect a stronger immune status 
which could have beneficial impact on reducing the risk of pancreatic cancer (20). Moreover, 
experimental studies found a similar protective effect for increased levels of IgG. Hamanaka et al., 
found circulating IgG antibodies to be a favourable prognostic factor for pancreatic cancer (60). In a 
recent publication, Follia et al. presented novel metabolic subtypes in pancreatic cancer and observed 
that the high immune infiltrated tumours had a better prognosis (61).  
 
Regarding the stronger inverse association observed between IgG levels and pancreatic cancer, 
presented in women in our study, we suggest that this may indicate that sex is an effect modifier in 
this association given the differential distribution of immunoglobulin levels between sex that has been 
described previously (62). 
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The Swedish AMORIS cohort is one of the largest prospective cohort studies with detailed information 
on a range of serum biomarkers, including large number of baseline measurements of serum markers 
of the humoral immune system, all measured at the same clinical laboratory (63) at baseline health 
examinations during the period 1985 to 1996. The cohort has a 30+ year follow-up in Swedish national 
registers, including the Cancer, Patient, Census and Cause-of-Death registers, as well as quality 
registers for specific cancer sites. All participants of the AMORIS study were included by analysing 
blood and/or urine samples from health check-ups in non-hospitalized persons (64). However, any 
healthy cohort effect would not affect the internal validity of our study. The external validity of the 
study is not compromised given that the cancer incidence in the AMORIS population is comparable to 
the reported incidence in the Swedish population (35). 
 
It was a limitation that immunoglobulin E (IgE), a serum biomarker of allergies studied previously in 
relation with pancreatic cancer (65), was only measured for a small subset of participants, so that it 
could not be assessed in relation to risk of pancreatic cancer. In addition, repeated measurements 
would have been helpful to verify the lag time between changes in markers of the humoral immune 
system and risk of pancreatic cancer. However, most of the individuals did not have multiple 
measurements. Information on other possible confounders such as BMI and smoking status was not 
available on AMORIS, therefore all models were adjusted for Charlson Comorbidity Index as a proxy 
for lifestyle factors. Biological material was unfortunately not available for further analyses. Molecular 
pathological analyses, such as the presence of immune cell infiltrates on the tumour tissue samples, 
can be an important resource in future studies to explore the potential association of the immune 
system, microbiome, lifestyle factors and pancreatic cancer development and to validate the 
epidemiological findings. 
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Conclusion 
To our knowledge, this study is the first prospective cohort study evaluating the association between 
pre-diagnostic serum markers of the overall humoral immune response and the risk of pancreatic 
cancer. We observed an inverse association between pre-diagnostic serum levels of IgG and the risk 
of pancreatic cancer. Our findings highlight the need to investigate the roles of different components 
of humoral immunity and agents that may cause a humoral immune response related to pancreatic 
cancer. Future studies could provide further insight into potential biological mechanisms by exploring 
longitudinal data such as repeated measurements of pre-diagnostic serum markers of the humoral 
immune system. Moreover, molecular pathological epidemiological studies, exploring tumour tissues, 
can potentially untangle the interlink between lifestyle factors, microbiome, carcinogenesis and the 
immune system (66-68).  
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Tables 
Table 1 Descriptive statistics of study population with a measurement of IgG. 
 
 
 
 
 
 
 
 Pancreatic cancer 
N = 689 
n (%) 
No pancreatic cancer 
N = 135,532 
n (%) 
Mean Age (years) (SD) 55.8 (11.37)  47.1 (14.33) 
< 55 319 (46.30) 95,342 (70.35) 
≥ 55 370 (53.70) 40,190 (29.65) 
Gender   
Men 388 (56.31)  68,995 (50.91) 
Women  301 (43.69) 66,537 (49.09) 
SES   
Unclassified/Missing 74 (10.74) 13,561 (10.01) 
Low 283 (41.07) 59,611 (43,98) 
High 332 (48.19) 62,360 (46.01) 
Education   
Missing 109 (15.82) 8,594 (6.34) 
Low 211 (30.62) 37,876 (27.95) 
Middle 241 (34.98) 55,617 (41.04) 
High 128 (18.58) 33,445 (24.68) 
Charlson Comorbidity Index   
0 622 (90.28) 126,594 (93.41) 
1 49 (7.11) 6,265 (4.62) 
2 13 (1.89) 1,565 (1.15) 
3+ 5 (0.73) 1,108 (0.82) 
Mean follow-up time (years) (SD) 13.1 (7.64) 21.3 (6.67) 
Glucose (mmol/L)   
Mean (SD) 5.34 (1.71) 5.01 (1.28) 
< 5.60 mmol/L 501 (72.71) 107,538 (79.35) 
5.60 – 6.99 mmol/L  107 (15.53) 14,352 (10.59) 
≥ 7.00 mmol/L  48 (6.97) 4,040 (2.98) 
Missing 33 (4.79) 9,602 (7.08) 
IgG (g/L)   
Mean (SD) 11.17 (2.77) 11.55 (3.03) 
< 6.10 g/L 14 (2.03) 1,493 (1.10) 
6.10 – 14.99 g/L 601 (87.23) 116,704 (86.11) 
≥ 15.00 g/L 74 (10.74) 17,335 (12.79) 
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Table 2 Hazard ratio (HR) for risk of pancreatic cancer, in the study population with a measurement 
of IgG, with 95% confidence intervals (CI) using Cox proportional hazards model. 
 Pancreatic cancer/Total 
N 
Hazard Ratio1 
(95 % CI) 
IgG (g/L)   
< 6.10 g/L 14/1,507 1.69 (0.99-2.87) 
6.10 – 14.99 g/L 601/117,305 1.00 (ref) 
≥ 15.00 g/L 74/17,409 0.82 (0.64-1.05) 
P-value for trend  0.027 
1 Adjusted for age, gender, education, CCI and serum glucose (continuous variable) 
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Table 3 Hazard ratio (HR) for risk of pancreatic cancer stratified by gender, in the study population 
with a measurement of IgG, with 95% confidence intervals from Cox proportional Hazards model. 
 Hazard Ratio1 
(95 % CI) 
Gender Male Female 
Pancreatic cancer/Total (n) 388/69,383 301/66,838 
IgG (g/L)   
< 6.10 g/L 1.46 (0.65-3.27) 1.98 (0.97-4.00) 
6.10 – 14.99 g/L 1.00 (Ref) 1.00 (Ref) 
≥ 15.00 g/L 0.95 (0.69-1.29)   0.64 (0.43-0.97)  
P value for interaction 0.003 
1 Adjusted for age, education, CCI and serum glucose (continuous variable). 
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Table 4 Descriptive statistics of study population with a measurement of IgA. 
 
 
 
 
 
 
 
 
 
 Pancreatic cancer 
N = 169 
n (%) 
No pancreatic cancer 
N = 41,731 
n (%) 
Mean Age (years) (SD)  60.3 (12.07) 49.6 (16.10) 
< 55  58 (34.32) 27,142 (65.04) 
≥ 55  111 (65.68) 14,589 (34.96) 
Gender   
Men 69 (40.83) 14,999 (35.94) 
Women   100 (59.17) 26,732 (64.06) 
SES   
Unclassified/Missing 27 (15.98) 7,499 (17.97) 
Low  69 (40.83)  18,137 (43.46) 
High  73 (43.20) 16,095 (38.57) 
Education   
Missing 14 (8.28) 2,358 (5.65) 
Low  50 (29.59)  10,787 (25.85) 
Middle 64 (37.87)  17,734 (42.50) 
High  41 (24.26)  10,852 (26.00) 
Charlson Comorbidity Index   
0 138 (81.66) 37,290 (89.36) 
1 22 (13.02) 2,950 (7.07) 
2 7 (4.14) 856 (2.05) 
3+  2 (1.18) 635 (1.52) 
Mean follow-up time (years) (SD) 8.8 (5.88) 16.5 (5.22) 
Glucose (mmol/L)   
Mean (SD) 5.50 (1.76) 5.08 (1.42) 
< 5.60 mmol/L 96 (56.80) 25,481 (61.06) 
5.60 – 6.99 mmol/L  25 (14.79) 3,990 (9.56) 
≥ 7.00 mmol/L  11 (6.51) 1,315 (3.15) 
Missing 37 (21.89) 10,945 (26.23) 
IgA (g/L)   
Mean (SD)  2.47 (1.20) 2.32 (1.20) 
< 3.66 g/L  151 (89.35)  37,228 (89.21) 
≥ 3.66 g/L  18 (10.65)   4,503 (10.79) 
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Table 5 Hazard ratio (HR) for risk of pancreatic cancer, in the study population with a measurement 
of IgA, with 95% confidence intervals (CI) using Cox proportional hazards model. 
 Pancreatic cancer/Total 
N 
Hazard Ratio1 
(95 % CI) 
IgA (g/L)   
< 3.66 g/L 151/37,379 1.00 (ref) 
≥ 3.66 g/L 18/4,521 0.70 (0.39-1.26) 
1 Adjusted for age, education, CCI and serum glucose (continuous variable). 
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Table 6 Descriptive statistics of study population with a measurement of IgM. 
 
 
 
 
 
 
 
 
 
 Pancreatic cancer 
N = 117 
n (%) 
No pancreatic cancer 
N = 29,802 
n (%) 
Mean Age (years) (SD)  60.9 (11.76) 50.8 (16.25) 
< 55  36 (30.77) 18,613 (62.46) 
≥ 55  81 (69.23) 11,189 (37.54) 
Gender   
Men 48 (41.03)  10,852 (36.41) 
Women  69 (58.97) 18,950 (63.59) 
SES   
Unclassified/Missing 18 (15.38) 5,675 (19.04) 
Low 51 (43.59) 12,759 (42.81) 
High 48 (41.03) 11,368 (38.15) 
Education   
Missing 8 (6.84) 1,658 (5.56) 
Low 37 (31.62) 7,885 (26.46) 
Middle 43 (36.75) 12,585 (42.23) 
High 29 (24.79) 7,674 (25,75) 
Charlson Comorbidity Index   
0 88 (75.21) 26,205 (87.93) 
1 20 (17.09) 2,349 (7.88) 
2 6 (5.13) 697 (2.34) 
3+ 3 (2.56) 551 (1.85) 
Mean follow-up time (years) (SD) 8.15 (5.53) 15.4 (4.73) 
Glucose (mmol/L)   
Mean (SD) 5.53 (1.59) 5.19 (1.51) 
< 5.60 mmol/L 60 (51.28) 16,259 (54.56) 
5.60 – 6.99 mmol/L  19 (16.24) 3,140 (10.54) 
≥ 7.00 mmol/L  8 (6.84) 1,046 (3.51) 
Missing 30 (25.64) 9,357 (31.40) 
IgM (g/L)   
Mean (SD) 1.11 (0.72) 1.28 (0.96) 
< 1.40 g/L 90 (76.92) 20,330 (68.22) 
≥ 1.40 g/L 27 (23.08) 9,472 (31.78) 
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Table 7 Hazard ratio (HR) for risk of pancreatic cancer, in the study population with a measurement 
of IgM, with 95% confidence intervals (CI) using Cox proportional hazards model. 
 Pancreatic cancer/Total 
N 
Hazard Ratio1 
(95 % CI) 
IgM (g/L)   
< 1.40 g/L 90/20,420 1.00 (ref) 
≥ 1.40 g/L 27/9499 0.82 (0.50-1.35) 
1 Adjusted for age, education, CCI and serum glucose (continuous variable). 
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Figures 
 
 
Figure 1 Adjusted dose-response association between serum levels of IgG (g/L) and risk of pancreatic 
cancer (HR) using restrictive cubic splines.  The direction of the hazard ratios observed in Tables 2 and 
3 was consistent with the shape of the curve, which presents a positive association for IgG levels lower 
(HR > 1.00)  than 11.00 g/L with pancreatic cancer risk and a protective effect for high levels of IgG 
(11.00 -20.00 g/L) (HR< 1.00). However, the inverse association was only statistically significant for 
concentrations of IgG between 11.00 g/L and 16.00 g/L. 
 
 
